{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:45:41Z","timestamp":1790484341011,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.xops.2021.100095","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T20:51:26Z","timestamp":1640119886000},"page":"100095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen"],"prefix":"10.1016","volume":"2","author":[{"given":"Michael J.","family":"Allingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyatham S.","family":"Mettu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Cousins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.xops.2021.100095_bib1","doi-asserted-by":"crossref","first-page":"ORSF5","DOI":"10.1167\/iovs.13-12789","article-title":"The prevalence of age-related eye diseases and visual impairment in aging: current estimates","volume":"54","author":"Klein","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2021.100095_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vis (Lond)"},{"issue":"10","key":"10.1016\/j.xops.2021.100095_bib3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(97)30079-7","article-title":"Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity","volume":"104","author":"Sunness","year":"1997","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.xops.2021.100095_bib4","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.ophtha.2006.12.023","article-title":"Cone- and rod-mediated dark adaptation impairment in age-related maculopathy","volume":"114","author":"Owsley","year":"2007","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.xops.2021.100095_bib5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ophtha.2008.03.009","article-title":"Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration","volume":"115","author":"Sunness","year":"2008","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.xops.2021.100095_bib6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamaophthalmol.2014.5963","article-title":"Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.xops.2021.100095_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.oret.2019.03.010","article-title":"Longitudinal study of visual function in dry age-related macular degeneration at 12 months","volume":"3","author":"Hsu","year":"2019","journal-title":"Ophthalmol Retin"},{"issue":"2","key":"10.1016\/j.xops.2021.100095_bib8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1167\/iovs.05-1222","article-title":"Development of a questionnaire to assess vision problems under low luminance in age-related maculopathy","volume":"47","author":"Owsley","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2021.100095_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ophtha.2019.12.009","article-title":"Natural history of geographic atrophy secondary to age-related macular degeneration: results from the prospective Proxima A and B clinical trials","volume":"127","author":"Holekamp","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.xops.2021.100095_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","article-title":"Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Chakravarthy","year":"2018","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.xops.2021.100095_bib11","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1167\/iovs.16-19520","article-title":"Enrichment of macular pigment enhances contrast sensitivity in subjects free of retinal disease: Central Retinal Enrichment Supplementation Trials\u2014report 1","volume":"57","author":"Nolan","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.xops.2021.100095_bib12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1167\/iovs.12-10715","article-title":"Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR Study","volume":"54","author":"Murray","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2021.100095_bib59","first-page":"173","article-title":"The burden of age-related macular degeneration: A value-based medicine analysis.","volume":"103","author":"Brown","year":"2005","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"9","key":"10.1016\/j.xops.2021.100095_bib14","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ophtha.2014.03.013","article-title":"Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene\/environment susceptibility study","volume":"121","author":"Jonasson","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.xops.2021.100095_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the US population","volume":"129","author":"Klein","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.xops.2021.100095_bib16","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1167\/iovs.14-14246","article-title":"Genetic determinants of age-related macular degeneration in diverse populations from the PAGE study","volume":"55","author":"Restrepo","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"10.1016\/j.xops.2021.100095_bib17","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1080\/10934529.2013.823323","article-title":"Nitrate-nitrogen levels in rural drinking water: is there an association with age-related macular degeneration?","volume":"48","author":"Klein","year":"2013","journal-title":"J\u00a0Environ Sci Healh A Tox Hazard Subst Environ Eng"},{"issue":"3","key":"10.1016\/j.xops.2021.100095_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/archopht.118.3.351","article-title":"Hypertension, cardiovascular disease, and age-related macular degeneration","volume":"118","author":"Hyman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.xops.2021.100095_bib19","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1167\/iovs.10-5429","article-title":"Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration","volume":"51","author":"Karunadharma","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.xops.2021.100095_bib20","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1167\/iovs.07-1352","article-title":"Mitochondrial proteomics of the retinal pigment epithelium at progressive stages of age-related macular degeneration","volume":"49","author":"Nordgaard","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.xops.2021.100095_bib21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.exer.2009.01.017","article-title":"A\u00a0human apoB100 transgenic mouse expresses human apoB100 in the RPE and develops features of early AMD","volume":"88","author":"Fujihara","year":"2009","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.xops.2021.100095_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1006\/exer.2002.2047","article-title":"The role of aging, high fat diet and blue light exposure in an experimental mouse model for basal laminar deposit formation","volume":"75","author":"Cousins","year":"2002","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.xops.2021.100095_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1167\/iovs.05-0719","article-title":"Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD","volume":"47","author":"Espinosa-Heidmann","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.xops.2021.100095_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ophtha.2012.11.037","article-title":"Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)","volume":"120","author":"Hagstrom","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.xops.2021.100095_bib25","first-page":"1542","article-title":"Inflammation and cell death in age-related macular degeneration: an immunopathological and ultrastructural model","volume":"3","author":"Ardeljan","year":"2014","journal-title":"J\u00a0Clin Med"},{"issue":"11","key":"10.1016\/j.xops.2021.100095_bib26","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/c0pp00207k","article-title":"Fundus autofluorescence and the bisretinoids of retina","volume":"9","author":"Sparrow","year":"2010","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/j.xops.2021.100095_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.preteyeres.2015.09.002","article-title":"Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration","volume":"51","author":"Ferrington","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2021.100095_bib28","first-page":"11","article-title":"Mitochondria: potential targets for protection in age-related macular degeneration","volume":"1074","author":"Brown","year":"2018"},{"issue":"4","key":"10.1016\/j.xops.2021.100095_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.mam.2012.04.006","article-title":"Retinal pigment epithelium response to oxidant injury in the pathogenesis of early age-related macular degeneration","volume":"33","author":"Mettu","year":"2012","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.xops.2021.100095_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.exer.2016.01.018","article-title":"Increased retinal mtDNA damage in the CFH variant associated with age-related macular degeneration","volume":"145","author":"Ferrington","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2021.100095_bib31","doi-asserted-by":"crossref","first-page":"100858","DOI":"10.1016\/j.preteyeres.2020.100858","article-title":"Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration","volume":"79","author":"Kaarniranta","year":"2020","journal-title":"Prog Retin Eye Res"},{"issue":"18","key":"10.1016\/j.xops.2021.100095_bib32","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1523\/JNEUROSCI.0190-15.2015","article-title":"Investigating mitochondria as a target for treating age-related macular degeneration","volume":"35","author":"Terluk","year":"2015","journal-title":"J\u00a0Neurosci"},{"issue":"9","key":"10.1016\/j.xops.2021.100095_bib33","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1167\/iovs.04-1224","article-title":"Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity","volume":"46","author":"Marin-Casta\u00f1o","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2021.100095_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2014.01.004","article-title":"Oxidative stress induces mitochondrial dysfunction and a protective unfolded protein response in RPE cells","volume":"69","author":"Cano","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.xops.2021.100095_bib35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1167\/iovs.03-0910","article-title":"Basal laminar deposit formation in APO B100 transgenic mice: complex interactions between dietary fat, blue light, and vitamin E","volume":"45","author":"Espinosa-Heidmann","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2021.100095_bib36","series-title":"Mitochondrial dysfunction in experimental mouse models of subRPE deposit formation and reversal by the mito-reparative drug MTP-131","author":"Cousins","year":"2016"},{"issue":"4","key":"10.1016\/j.xops.2021.100095_bib37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4103\/jovr.jovr_182_17","article-title":"The role of mitochondria in AMD: current knowledge and future applications","volume":"12","author":"Riazi-Esfahani","year":"2017","journal-title":"J\u00a0Ophthalmic Vis Res"},{"issue":"4","key":"10.1016\/j.xops.2021.100095_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ophtha.2012.10.007","article-title":"Histologic basis of variations in retinal pigment epithelium autofluorescence in eyes with geographic atrophy","volume":"120","author":"Rudolf","year":"2013","journal-title":"Ophthalmology"},{"issue":"31","key":"10.1016\/j.xops.2021.100095_bib39","doi-asserted-by":"crossref","first-page":"12915","DOI":"10.1073\/pnas.1100957108","article-title":"Structural plasticity of perisynaptic astrocyte processes involves ezrin and metabotropic glutamate receptors","volume":"108","author":"Lavialle","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.xops.2021.100095_bib40","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1007\/s11064-015-1563-8","article-title":"Fine astrocyte processes contain very small mitochondria: glial oxidative capability may fuel transmitter metabolism","volume":"40","author":"Derouiche","year":"2015","journal-title":"Neurochem Res"},{"issue":"11","key":"10.1016\/j.xops.2021.100095_bib41","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s11064-012-0824-z","article-title":"Beyond polarity: functional membrane domains in astrocytes and M\u00fcller cells","volume":"37","author":"Derouiche","year":"2012","journal-title":"Neurochem Res"},{"key":"10.1016\/j.xops.2021.100095_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.yjmcc.2014.03.011","article-title":"Mitochondrial reactive oxygen species production and elimination","volume":"73","author":"Nickel","year":"2014","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.xops.2021.100095_bib43","first-page":"1954","article-title":"Elamipretide protects RPE and improves mitochondrial function in models of AMD","volume":"58","author":"Kapphahn","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.xops.2021.100095_bib44","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/bph.12468","article-title":"Targeting mitochondrial cardiolipin and the cytochrome c\/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis","volume":"171","author":"Birk","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.xops.2021.100095_bib45","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/bph.12461","article-title":"First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics","volume":"171","author":"Szeto","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.xops.2021.100095_bib46","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1167\/iovs.16-19580","article-title":"Baseline MNREAD measures for normally sighted subjects from childhood to old age","volume":"57","author":"Calabr\u00e8se","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.xops.2021.100095_bib47","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/IAE.0000000000001002","article-title":"Visual function measures in early and intermediate age-related macular degeneration","volume":"36","author":"Chandramohan","year":"2016","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.xops.2021.100095_bib48","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1167\/iovs.13-13745","article-title":"Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration","volume":"55","author":"Jackson","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.xops.2021.100095_bib49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ophtha.2013.07.013","article-title":"Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography","volume":"121","author":"Farsiu","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.xops.2021.100095_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245824","article-title":"MultipleTesting.com: a tool for life science researchers for multiple hypothesis testing correction","volume":"16","author":"Menyhart","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2021.100095_bib51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ajo.2018.02.012","article-title":"Visual function metrics in early and intermediate dry age-related macular degeneration for use as clinical trial endpoints","volume":"189","author":"Cocce","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.xops.2021.100095_bib52","first-page":"701","article-title":"A\u00a0mitochondrial therapeutic reverses visual decline in mouse models of diabetes","volume":"8","author":"Alam","year":"2015","journal-title":"DMM Dis Model Mech"},{"issue":"1","key":"10.1016\/j.xops.2021.100095_bib53","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1152\/ajprenal.00366.2014","article-title":"Improving mitochondrial bioenergetics under ischemic conditions increases warm ischemia tolerance in the kidney","volume":"308","author":"Szeto","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"10.1016\/j.xops.2021.100095_bib54","doi-asserted-by":"crossref","first-page":"F970","DOI":"10.1152\/ajprenal.00697.2013","article-title":"Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation, and fibrosis","volume":"306","author":"Liu","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"14","key":"10.1016\/j.xops.2021.100095_bib55","doi-asserted-by":"crossref","first-page":"E1212","DOI":"10.1212\/WNL.0000000000005255","article-title":"Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy","volume":"90","author":"Karaa","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.xops.2021.100095_bib56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cardfail.2020.02.001","article-title":"Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial: effects of elamipretide in heart failure","volume":"26","author":"Butler","year":"2020","journal-title":"J\u00a0Card Fail"},{"issue":"12","key":"10.1016\/j.xops.2021.100095_bib57","article-title":"Novel mitochondria-targeting peptide in heart failure treatment","volume":"10","author":"Daubert","year":"2017","journal-title":"Circ Hear Fail"},{"issue":"3","key":"10.1016\/j.xops.2021.100095_bib58","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","article-title":"Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914521000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:20:19Z","timestamp":1763014819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914521000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2666914521000907"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2021.100095","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2021.100095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100095"}}